Genentech funds academic research to undermine drug pricing reforms amid Washington lobbying battles
Original framing: “STAT+: Genentech is soliciting research that can be used to blunt pharma reforms in Washington” — STAT News
The pharmaceutical industry has a long history of lobbying against drug pricing reforms, dating back to the 1990s battles over Medicare drug benefits. Industry-funded research has repeatedly been used to justify opposition to reforms, including the 2003 Medicare Modernization Act and the Affordable Care Act’s biosimilar provisions. This pattern demonstrates how corporate power systematically shapes policy narratives to delay or weaken public health protections.
Genentech’s solicitation of industry-funded research to blunt drug pricing reforms is not an isolated corporate tactic but a symptom of a deeper systemic issue: the capture of knowledge production by pharmaceutical interests to maintain regulatory status quo.
This pattern is deeply rooted in historical lobbying battles, where industry-funded studies have repeatedly delayed reforms that threaten profit margins, as seen in the 1990s Medicare drug benefit debates and the Affordable Care Act. The cross-cultural lens reveals alternative models—from Brazil’s price controls to Cuba’s public drug development—that prioritize public health over corporate interests, challenging the Western narrative of innovation as solely market-driven. Yet, marginalized voices, particularly those of patients and low-income communities, remain sidelined in these debates, their survival reduced to a bargaining chip in corporate lobbying wars. The solution lies in decoupling drug development from profit motives through public funding, enforcing transparency in academic-industry relationships, and empowering grassroots advocacy to reclaim healthcare as a human right rather than a market transaction.